Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes (SUPRACOR)

This study has been completed.
Information provided by (Responsible Party):
Technolas Perfect Vision GmbH Identifier:
First received: June 28, 2011
Last updated: May 19, 2015
Last verified: May 2015

This clinical study has been planned to determine the effectiveness of a special laser treatment intended to correct both near and distance vision in patients who have undergone previous cataract surgery.

Condition Intervention Phase
Device: Supracor
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Study to Evaluate the Safety and Effectiveness of the Supracor Presbyopic Treatment Algorithm for Pseudophakic Eyes Using Lasik

Further study details as provided by Technolas Perfect Vision GmbH:

Primary Outcome Measures:
  • The percentage of treated eyes with a best corrected high contrast distance VA of 20/25 or better [ Time Frame: 6M ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The percentage of treated eyes within +/- 1.00D of target refraction [ Time Frame: 6M ] [ Designated as safety issue: No ]
  • The percentage of treated eyes within +/- 0.50D of target refraction [ Time Frame: 6M ] [ Designated as safety issue: No ]
  • The percentage of treated eyes with an uncorrected high contrast near VA of 20/40 or better [ Time Frame: 6M ] [ Designated as safety issue: No ]
  • Stability analysis: change of ≤ 1D MRSE between two consecutive post-op visits [ Time Frame: 6M ] [ Designated as safety issue: No ]
  • Preservation of VA: Loss of more than 2 lines in BCVA for distance vision [ Time Frame: 6M ] [ Designated as safety issue: Yes ]
  • The percentage of treated eyes with a best-distance corrected high contrast distance VA of 20/40 or better [ Time Frame: 6M ] [ Designated as safety issue: Yes ]
  • The percentage of treated eyes with an induced subjective manifest refraction cylinder not within +/- 2.00D [ Time Frame: 6M ] [ Designated as safety issue: Yes ]
  • Cumulative incidence of AEs [ Time Frame: 6M ] [ Designated as safety issue: Yes ]
  • Cumulative incidence subjective symptoms [ Time Frame: 6M ] [ Designated as safety issue: Yes ]

Enrollment: 33
Study Start Date: June 2011
Study Completion Date: October 2014
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Supracor
Study arm will consist of patients who have undergone previous cataract surgery with implantation of a monofocal IOL. The Supracor procedure will be performed on the non-dominant pseudophakic eye of these patients.
Device: Supracor

The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.

The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances.

Other Names:
  • PresbyLASIK
  • Multifocal Ablation

Detailed Description:

This clinical study has been planned to evaluate the safety and effectiveness of the SUPRACOR presbyopic excimer laser treatment algorithm for near myopic and near hyperopic indications, with or without astigmatism, when performed on the cornea of pseudophakic eyes implanted with a monofocal IOL.


Ages Eligible for Study:   45 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be at least 45 years old
  • Subjects must read, understand, and sign an Informed Consent Form (ICF).
  • Subjects must be willing and able to return for scheduled follow-up examinations through 6 months after surgery.
  • Subjects must have undergone previous uncomplicated cataract surgery with monofocal IOL implant in the study eye at least 3 months prior to study enrollment.
  • Subjects must have up to +/- 2.0 (D) of absolute spherical myopia or hyperopia (not spherical equivalent), with up to +/- 2.0 D of refractive astigmatism (NOT corneal astigmatism) by manifest subjective refraction. The spherical equivalent must be no more than +/- 2.0 D.
  • Subjects who have be screened successfully for acceptance of the SUPRACOR simulation

Exclusion Criteria:

  • Subjects for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in less than 250 microns of remaining corneal thickness below the flap postoperatively.
  • Subjects for whom the preoperative assessment of the ocular topography indicates that one or both eyes are not suitable candidates for treatment based upon the suggested computer-simulated treatment plan (e.G. Keratoconus).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01387360

Asian Eye Institute
Makati, Manila, Philippines
Sponsors and Collaborators
Technolas Perfect Vision GmbH
Study Director: Robert Ang, M.D. Asian Eye Institute